Company:  RIGEL PHARMACEUTICALS INC (RIGL)
Form Type:  SC 13G/A
Filing Date:  7/11/2022 
CIK:  0001034842 
Address:  1180 VETERANS BOULEVARD 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.75  
Change: 
-0.008 (-1.07%)  
Trade Time: 
Nov 25  
Market Cap: 
$129.80M
Trade RIGL now with 

© 2022  
Description of Business
We are a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Our pioneering research focuses on signaling pathways that are critical to disease mechanisms. Our first product approved by the FDA is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients.
Register and access this filing in:     
  FORM SC 13G/A